Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy.
Publication/Presentation Date
7-1-2020
Abstract
Intraperitoneal vancomycin is the first-line therapy in the management of peritoneal dialysis (PD)-related peritonitis. However, due to the paucity of data, vancomycin dosing for peritonitis in patients on automated peritoneal dialysis (APD) is empiric and based on clinical experience rather than evidence. Studies in continuous ambulatory peritoneal dialysis (CAPD) patients have been used to provide guidelines for dosing and are often extrapolated for APD use, but it is unclear whether this is appropriate. This review summarizes the available pharmacokinetic data used to inform optimal dosing in patients on CAPD or APD. The determinants of vancomycin disposition and pharmacodynamic effects are critically summarized, knowledge gaps explored, and a vancomycin dosing algorithm in PD patients is proposed.
Volume
40
Issue
4
First Page
384
Last Page
393
ISSN
1718-4304
Published In/Presented At
Lam, E., Lien, Y. T. K., Kraft, W. K., Piraino, B., Vozmediano, V., Schmidt, S., & Zhang, J. (2020). Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 40(4), 384–393. https://doi.org/10.1177/0896860819889774
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
32065053
Department(s)
Administration and Leadership
Document Type
Article